Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.82 USD
-0.06 (-2.93%)
Updated May 29, 2024 04:00 PM ET
After-Market: $1.83 +0.01 (0.55%) 6:38 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
PACB 1.82 -0.06(-2.93%)
Will PACB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PACB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PACB
Reasons to Retain PacBio (PACB) Stock in Your Portfolio
Pacific Biosciences of California, Inc. (PACB) Is a Trending Stock: Facts to Know Before Betting on It
PACB: What are Zacks experts saying now?
Zacks Private Portfolio Services
PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up
Pacific Biosciences (PACB) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
Other News for PACB
Cathie Wood's Ark Innovation ETF Sees Sharp Decline Among Top Holdings — Here Are 10-Largest Losers Within ARKF
NVIDIA, Dell Technologies, Super Micro Computer among premarket gainers' pack
How Is The Market Feeling About Pacific Biosciences?
Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases
PacBio and Ambry selected by University of California and the GREGoR Consortium